AbbVie Inc. entered the obesity market by in-licensing GUBamy, a long-acting amylin analog, a modest but important first step to challenge Eli Lilly and Novo Nordisk. AbbVie's will pay $350 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback